Hôpital Universitaire Pitié Salpêtrière

Paris, Île-de-France Region 75013

1 studies enrolling now · 5 studies all time

What they study most

Cancer Harboring BRAF Alterations, EBV Related PTCL, NOS, EBV-Positive DLBCL, NOS, EBV-Related Hodgkin Lymphoma, EBV-Related Lymphoproliferative Disorder, EBV-Related Non-Hodgkin Lymphoma, EBV-Related PTLD, Epstein-Barr Virus Associated Lymphoma, HGG, LGG, Myelofibrosis, NASH - Nonalcoholic Steatohepatitis

Studies at this site

• A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations — Recruiting now
• A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) — Running, not enrolling
• Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis — Running, not enrolling
• An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas — Stopped early
• Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations — Stopped early